Rolapitant and Thioridazine Interaction
Drug interaction information between Rolapitant and Thioridazine.
Rolapitant and Thioridazine have a documented major interaction in FDA labeling.
FDA drug labeling documents a major-severity interaction between Rolapitant and Thioridazine. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Rolapitant prevents the body from processing thioridazine, causing it to build up to unsafe levels. High levels of this drug can cause life-threatening heart rhythm issues.
What To Do
This combination must be avoided. Ask your doctor for a different treatment option for either your nausea or your mental health condition.
Rolapitant Also Interacts With
- Pimozide major
- Rifampin moderate
- Rosuvastatin minor
- Warfarin minor
- Methotrexate minor
Thioridazine Also Interacts With
- Fluoxetine major
- Paroxetine major
- Abiraterone moderate
- Darifenacin moderate
- Tetrabenazine moderate
Frequently Asked Questions
Can I take Rolapitant and Thioridazine together?
This is a major interaction. This combination must be avoided. Ask your doctor for a different treatment option for either your nausea or your mental health condition.
How serious is the interaction between Rolapitant and Thioridazine?
This interaction is classified as "major" severity by the FDA. Major interactions may be life-threatening or cause serious side effects.
Why do Rolapitant and Thioridazine interact?
Rolapitant prevents the body from processing thioridazine, causing it to build up to unsafe levels. High levels of this drug can cause life-threatening heart rhythm issues.
Understanding the Rolapitant and Thioridazine Interaction
FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Rolapitant belongs to the NK1 Receptor Antagonist (Antiemetic) class and Thioridazine belongs to the Typical Antipsychotic (Phenothiazine) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Rolapitant prevents the body from processing thioridazine, causing it to build up to unsafe levels. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Rolapitant has 9 total documented interactions on file in this dataset, and Thioridazine has 17. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: This combination must be avoided. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Rolapitant or Thioridazine based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.